Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Human Papillomavirus (HPV) Associated Cancer. According to GlobalData, Phase I drugs for Human Papillomavirus (HPV) Associated Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eganelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eganelisib overview
Eganelisib is under development for the treatment of solid tumors including metastatic renal cell cancer, triple negative breast cancer, metastatic melanoma, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, mesothelioma, adrenocortical carcinoma and metastatic urothelial cancer, human papillomavirus (HPV) positive or HPV negative SCCHN (oral cavity, pharynx, hypopharynx, larynx, nasopharyngeal [including undifferentiated nasopharyngeal carcinoma). The drug candidate is administered through oral route in the form of capsule. It acts by targeting phosphoinositide-3-kinase gamma (PI3K-gamma). It was also under development for the treatment of soft tissue sarcoma, prostate cancer, metastatic ovarian cancer, colon cancer, glioblastoma multiforme, microsatellite-stable gallbladder carcinoma, ovarian cancer, peritoneal and colorectal cancer.
See Also:
Infinity Pharmaceuticals overview
Infinity Pharmaceuticals is a biopharmaceutical company which discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. The company is evaluating IPI-549 as a monotherapy and in a combination therapy in various clinical trials for the treatment of various indications such advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma and myeloid-derived suppressor cells (MDSC). The company has collaborations with other biopharmaceuticals companies for the development of its pipeline programs. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Eganelisib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
